CN107735397A - Gpr55受体活性选择性调节剂：苯并吡喃吡唑衍生物 - Google Patents

Gpr55受体活性选择性调节剂：苯并吡喃吡唑衍生物 Download PDF

Info

Publication number
CN107735397A
CN107735397A CN201680039783.1A CN201680039783A CN107735397A CN 107735397 A CN107735397 A CN 107735397A CN 201680039783 A CN201680039783 A CN 201680039783A CN 107735397 A CN107735397 A CN 107735397A
Authority
CN
China
Prior art keywords
methoxy
pyrazole
dihydro
dimethylbenzopyran
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680039783.1A
Other languages
English (en)
Chinese (zh)
Inventor
纳丁·雅格罗维克
宝拉·莫拉莱斯·拉扎罗
露丝·罗斯
劳伦·怀特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
University of Toronto
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto, Consejo Superior de Investigaciones Cientificas CSIC filed Critical University of Toronto
Publication of CN107735397A publication Critical patent/CN107735397A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680039783.1A 2015-05-05 2016-04-27 Gpr55受体活性选择性调节剂：苯并吡喃吡唑衍生物 Pending CN107735397A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201530608A ES2593057B1 (es) 2015-05-05 2015-05-05 Moduladores selectivos de la actividad del receptor GPR55: derivados de cromenopirazol
ESP201530608 2015-05-05
PCT/ES2016/070314 WO2016177922A1 (es) 2015-05-05 2016-04-27 Moduladores selectivos de la actividad del receptor gpr55: derivados de cromenopirazol

Publications (1)

Publication Number Publication Date
CN107735397A true CN107735397A (zh) 2018-02-23

Family

ID=57217626

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680039783.1A Pending CN107735397A (zh) 2015-05-05 2016-04-27 Gpr55受体活性选择性调节剂：苯并吡喃吡唑衍生物

Country Status (13)

Country Link
US (1) US10435412B2 (https=)
EP (1) EP3305794B1 (https=)
JP (1) JP2018515499A (https=)
KR (1) KR20180002717A (https=)
CN (1) CN107735397A (https=)
AU (1) AU2016257025A1 (https=)
BR (1) BR112017023834A2 (https=)
CA (1) CA2985021A1 (https=)
ES (1) ES2593057B1 (https=)
IL (1) IL255420A0 (https=)
MX (1) MX2017014145A (https=)
RU (1) RU2017138563A (https=)
WO (1) WO2016177922A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109420174B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr18及其调节剂在防治免疫系统疾病中的应用
CN109420173B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr55及其调节剂在防治免疫系统疾病中的应用
EP4472947A1 (en) * 2022-03-07 2024-12-11 Firmenich Incorporated Sweetener compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624102A (en) * 1969-05-21 1971-11-30 Warner Lambert Co Substituted benzopyranopyrazoles
WO2009010824A1 (en) * 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands
WO2010109050A1 (es) * 2009-03-24 2010-09-30 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromenopirazoles como ligandos de receptores de cannabinoides
WO2014013117A1 (es) * 2012-07-18 2014-01-23 Consejo Superior De Investigaciones Científicas (Csic) Cromenopirazoldionas como derivados cannabinoides de quinonas con actividad antitumoral

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0010960D0 (en) 2000-05-05 2000-06-28 Glaxo Group Ltd Assay
WO2004074844A1 (en) * 2003-02-18 2004-09-02 Astrazeneca Ab Screening assays for cannabinoid-ligand-type modulators of gpr55
EP2079736B1 (en) * 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
ES2548789B1 (es) 2014-03-18 2016-08-08 Consejo Superior De Investigaciones Científicas (Csic) Nuevas cromenoquinonas moduladoras de receptores cannabinoidescb2 con actividad antitumoral

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624102A (en) * 1969-05-21 1971-11-30 Warner Lambert Co Substituted benzopyranopyrazoles
WO2009010824A1 (en) * 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands
WO2010109050A1 (es) * 2009-03-24 2010-09-30 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromenopirazoles como ligandos de receptores de cannabinoides
WO2014013117A1 (es) * 2012-07-18 2014-01-23 Consejo Superior De Investigaciones Científicas (Csic) Cromenopirazoldionas como derivados cannabinoides de quinonas con actividad antitumoral

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAULA MORALES，等: "Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
US20180201620A1 (en) 2018-07-19
JP2018515499A (ja) 2018-06-14
EP3305794A1 (en) 2018-04-11
ES2593057A1 (es) 2016-12-05
AU2016257025A1 (en) 2017-11-30
WO2016177922A1 (es) 2016-11-10
EP3305794B1 (en) 2020-02-05
EP3305794A4 (en) 2018-11-07
IL255420A0 (en) 2017-12-31
RU2017138563A3 (https=) 2019-06-06
BR112017023834A2 (pt) 2018-07-31
MX2017014145A (es) 2018-06-20
CA2985021A1 (en) 2016-11-10
KR20180002717A (ko) 2018-01-08
RU2017138563A (ru) 2019-06-05
ES2593057B1 (es) 2017-09-12
US10435412B2 (en) 2019-10-08

Similar Documents

Publication Publication Date Title
CN106536508B (zh) 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的化合物
CN101511796B (zh) 咪唑衍生物
CN107001347B (zh) 氧杂螺环类衍生物、其制备方法及其在医药上的应用
EP3144308B1 (en) Nitrogen-containing heterocyclic compound
TW201910328A (zh) 雜環化合物
CA2765678A1 (en) Substituted hydroxamic acids and uses thereof
TW202126643A (zh) 雜環化合物
MX2013005897A (es) Derivados de benzopirazina sustituidos como inhibidores de cinasa del receptor del factor de crecimiento de fibroblasto (fgfr) para el tratamiento de enfermedades cancerigenas.
WO2006085685A1 (ja) ピラゾール化合物
EA035544B1 (ru) Производные тетрагидроизохинолина
MX2010011358A (es) Indoles como moduladores del receptor nicotinico de acetilcolina subtipo alfa-71.
WO2024199109A1 (zh) 一类作为wrn解旋酶抑制剂的杂环类化合物及其制备方法和应用
KR102361418B1 (ko) (S)-(2-(6-클로로-7-메틸-1H-벤조[d]이미다졸-2-일)-2-메틸피롤리딘-1- 일)(5-메톡시-2-(2H-1,2,3-트리아졸-2-일)페닐)메타논의 결정형 및 오렉신 수용체 길항제로서의 그 용도
WO2024199108A1 (zh) 作为wrn解旋酶抑制剂的化合物
CN107735397A (zh) Gpr55受体活性选择性调节剂：苯并吡喃吡唑衍生物
KR20160062187A (ko) 피페라진 유도체 및 약제로서의 이의 용도
JP2011500728A (ja) 疾患の処置に有用なニコチン性アセチルコリン受容体の（１，４−ジアザ−ビシクロ［３．２．２］ノン−６−エン−４−イル）−ヘテロシクリル−メタノンリガンド
CN116655602A (zh) PI3Kα变构抑制剂
TW201504227A (zh) 環狀胺基甲基嘧啶衍生物
AU2018289939B2 (en) Heterocyclic compound
JP5642154B2 (ja) α７ｎＡＣｈＲのインドール誘導体モジュレータ
Kim et al. Novel N-acyl-carbazole derivatives as 5-HT7R antagonists
CA2591123A1 (en) Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CN110114355A (zh) 用于治疗癌症的噁唑衍生物
HK40067799B (zh) 芳香杂环衍生物作为免疫调节剂的制备及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180223

WD01 Invention patent application deemed withdrawn after publication